These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19786099)

  • 1. Dynamics of target-mediated drug disposition.
    Peletier LA; Gabrielsson J
    Eur J Pharm Sci; 2009 Dec; 38(5):445-64. PubMed ID: 19786099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
    Gibiansky L; Gibiansky E
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target-mediated drug disposition and dynamics.
    Mager DE
    Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.
    Peletier LA; Gabrielsson J
    J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):429-51. PubMed ID: 22851162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model.
    Yan X; Krzyzanski W
    J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):141-6. PubMed ID: 22215144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approximations of the target-mediated drug disposition model and identifiability of model parameters.
    Gibiansky L; Gibiansky E; Kakkar T; Ma P
    J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):573-91. PubMed ID: 19005743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.
    Koch G; Jusko WJ; Schropp J
    J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):17-26. PubMed ID: 28074395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.
    Koch G; Jusko WJ; Schropp J
    J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):27-42. PubMed ID: 28074396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target-mediated drug disposition model for drugs that bind to more than one target.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors.
    Yamazaki S; Shen Z; Jiang Y; Smith BJ; Vicini P
    Drug Metab Dispos; 2013 Jun; 41(6):1285-94. PubMed ID: 23557746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.
    Marathe A; Krzyzanski W; Mager DE
    J Pharmacokinet Pharmacodyn; 2009 Jun; 36(3):199-219. PubMed ID: 19434483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.
    Eudy RJ; Riggs MM; Gastonguay MR
    AAPS J; 2015 Sep; 17(5):1280-4. PubMed ID: 26077506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mathematical comparison between volume of distribution (V) and volume of distribution at steady-state (Vss) utilizing model-independent approach.
    Sobol E; Bialer M
    Biopharm Drug Dispos; 2004 Mar; 25(2):99-101. PubMed ID: 14872558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.
    Gibiansky L; Ng CM; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2024 Apr; ():. PubMed ID: 38639818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Steady-States Highlight Interesting Target-Mediated Disposition Properties.
    Gabrielsson J; Peletier LA
    AAPS J; 2017 May; 19(3):772-786. PubMed ID: 28144911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model to describe myocardial drug disposition in the dog.
    Kates RE; Jaillon P
    J Pharmacol Exp Ther; 1980 Jul; 214(1):31-6. PubMed ID: 7391969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of kinetic N-order model in description of active substance release from various drug forms. Part 1. Premises and mathematical analysis of the N-order model.
    Marciniak DM; Dryś A; Pluta J; Kubis AA
    Acta Pol Pharm; 2008; 65(1):101-5. PubMed ID: 18536181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dynamic paradigm in psychopathology: "chaos theory", from physics to psychiatry].
    Pezard L; Nandrino JL
    Encephale; 2001; 27(3):260-8. PubMed ID: 11488256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-target residence time and its implications for lead optimization.
    Copeland RA; Pompliano DL; Meek TD
    Nat Rev Drug Discov; 2006 Sep; 5(9):730-9. PubMed ID: 16888652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.